DECEMBER 2024LIFE SCIENCES REVIEW 19By Dae Wook Lee, Medicine (MbChB), MBA, MSC, BSc, Medical Director and Medical Franchise, Head for CRM, Neuroscience, and Gene Therapy, NovartisIMPLICATION OF GENERATIVE AI IN BIOTECHNOLOGY io: Dr. Dae Wook Lee is a Medical Director of Novartis Korea in Cardiology, Renal, Metabolism, Neuroscience, and Gene Therapy. He was Head of Medical Portfolio Management in Rare Disease, Gastroenterology, PDT, Neuroscience, and New Molecular entities from the Asia-Pacific Region of Takeda Pharmaceutical Ltd Pte. He obtained his Medical Degree from the University of Warwick, U.K., awarded MbChB Medicine & Surgery, and completed MSC Genetic Epidemiology at the Medical Research Unit in the University of Sheffield, U.K., with an additional BSc Biomedical Science degree. He also holds an Executive MBA from Harris College of Business, Faulkner University in North Alabama. Dr. Lee received the Best Research Award in the International Research Awards of Cardiology and Cardiovascular Medicine in 2022. His main clinical research interests lie in genetics and novel medical statistical analysis of Rare Diseases, including Cardiology, Rare Hematology, Rare Metabolic Diseases including Fabry & Gaucher's Disease, Rare Immunology including Hereditary AngioEdema (HAE), etiology and pathophysiology of inflammatory bowel disease (IBD), and Rare Neuroscience disease including Paediatric Epilepsy and Narcolepsy Type 1. One of his recent publications includes Network Meta-analysis of Comparative Efficacy and Safety of Combination Therapy with Angiotensin II Receptor Blockers and Amlodipine in Asian Hypertensive Patients and Retrospective Analysis of Ulcerative Colitis Real-world Evidence Implementing Exploratory Propensity Score Matching (PSM) analysis. Dr. Lee is also a member of the Korean Society of Pharmaceutical Medicine (KSPM).The rapid progress in generative AI has unlocked unprecedented opportunities for innovation and discovery across various domains, and the biotechnology industry is poised to reap the countless benefits of this transformative technology.Advancement of Generative AI Generative AI, a groundbreaking branch of artificial intelligence, has demonstrated remarkable capabilities in producing novel and diverse data samples, from molecular structures to biological images. This technology has found its way into the heart of biotechnology, revolutionizing how researchers approach challenges such as drug discovery, protein engineering, and personalized medicine.Implication of Generative AI in Drug Discovery In the drug discovery field, generative AI models like Generative Adversarial Networks (GANs) and Variational Autoencoders (VAEs) have shown immense potential. These models can generate novel molecular structures with desired properties, significantly accelerating the identification of potential drug candidates and streamlining the drug development process. For instance, researchers have leveraged generative AI to design and optimize enzyme catalysts, antibodies, and other therapeutic agents with enhanced functionalities. Such advancements can revolutionize the pharmaceutical industry, propelling the development of more targeted and effective treatments for a wide range of medical conditions.Biological Image Synthesis with AI Beyond drug discovery, generative AI has also made remarkable strides within the biological image synthesis realm. By generating realistic and diverse synthetic BDae Wook LeeCXO INSIGHTS
< Page 9 | Page 11 >